1- Marchesini G. et al, Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome. Hepatology 2003;37:917-923
2- Matthew J. Armstrong MJ. Et al, Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort Original Research Article Journal of Hepatology, Volume 56, Issue 1, January 2012, Pages 234-240
3- Ratziu V. et al Gastroentérologie Clinique et Biologique. Vol 33 - N° 8-9 P. 850-858 - août 2009
4- Ekstedt M. et al Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology. 2006 Oct;44(4):865-73
5- Gastaldelli A. et al, Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133:496-506, 2007)
6- Schindhelm RK. Et al, Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191:391–396
7- Tiikkainen M. et al, Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003 Mar;52(3):701-7.
8- Katsutaro Morino K, Petersen KF. Et al, Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction Diabetes December 2006 55:S9-S15
9- Musso G. et al, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010 Jul;52(1):79-104.
10- Sanyal AJ.et al, Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis N Engl J Med 2010; 362:1675-1685
Mise au point
Les urgences psychiatriques en médecine générale
Étude et pratique
Mortalité liée au tabac, le sevrage bénéfique quel que soit l’âge
Cas clinique
Le kyste osseux anévrismal
Recommandation
Le RGO du nourrisson